News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Kim M. Hirshfield

Articles by Kim M. Hirshfield

TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer

BySara M. Tolaney, MD, MPH,Paolo D’Amico,Liyi Jia,Kim M. Hirshfield,Fatima Cardoso

April 16th 2025

Latest Updated Articles

Trending on CancerNetwork

Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer

Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL

Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs

Muscle RNome Analysis Reveals 2 Molecular Subtypes Associated With Cancer Cachexia

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

© 2025 MJH Life Sciences^®

All rights reserved.